Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance

Abstract excerpt

From a public health perspective, new antibacterial agents should be evaluated and approved for use before widespread resistance to existing agents emerges. However, for multidrug-resistant pathogens, demonstration of superior efficacy of a new agent over a current standard-of-care agent is routinely feasible only when epidemic spread of these dangerous organisms has already occurred. One solution to enable...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibiotic Resistance in Bacteria
• Share to Antibiotics Pharmacokinetics and Efficacy
• Share to Pharmaceutical and Antibiotic Environmental Impacts